Introduction: Innate lymphoid cells (ILCs) can provide early cytokine help
Conclusions: These findings illustrate that chronic loss of PD-1 plays a role in ILC2 function and PD-1 expression can be modulated by PPAR-γ.
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| INTRODUCTION
Innate lymphoid cells (ILCs) are cytokine-producing cells that are typically associated with promoting tissuespecific immunity and as such are found in compartments including the gut, fat, and lungs of mice. ILC becomes functionally specialized during their development to express interferon γ (IFNγ) (ILC1), interleukin 5 (IL-5)/IL-13 (ILC2), or IL-17/IL-22 (ILC3). These subsets more or less mirror the cytokine-producing potential of adaptive T helper cells. 1 While natural killer (NK) cells are known for their cytotoxicity, the other ILCs appear to be involved in secreting cytokines important in host defense. ILC1s like NK cells produce IFN-γ, however, they only express the T-bet transcription factor and not Eomes, as NK cells. IL-33R (ST2), IL-17RB, and the receptor for thymic stromal lymphopoietin (TSLP). They have been attributed with a number of functions such as host defense against parasitic helminth infections in the gut, [6] [7] [8] inducing eosinophilia and airway hyper-responsiveness 9,10 as well as regulating fat metabolism 11 and wound healing. 12 The programmed cell death protein 1 (PD-1) is a checkpoint inhibitor of the immune system and is expressed primarily on lymphocytes during an immune response. 13 On the surface of T cells, PD-1 functions primarily as an inhibitory molecule by binding its ligands PD-L1 and PD-L2. Both of these ligands are induced on immune cells during inflammatory conditions and engagement of PD-1 on T cells dampens immune responses by reducing activating signals through the T cell receptor and costimulatory receptors. 13 This has made targeting PD-1 and its ligands an attractive immunotherapy against cancer, in particular when cancer cells themselves express PD-L1. 14 In addition, PD-L1 and PD-L2 engagement may regulate Th1 and Th2 immune responses respectively. 15 Expression of PD-L2 on subsets of dendritic cells (DC) and macrophages has been associated with inducing Th2 responses. [15] [16] [17] Genome-wide arrays identified a number of molecules that could be used to separate ILC2 from other ILC. 18 These included many molecules already associated with Th2 responses such as GATA3, IL-5, IL-13, and peroxisome proliferator-activated receptor-γ (PPAR-γ). PD-1 expression by ILC2 was another hallmark separating ILC2 from NK cells and other ILC subsets. 18 More recently PD-1 expression was detected early in ILC development, which was thought to play a role in the development of ILC responses and ILC2 could be depleted with anti-PD-1 antibody. 19 In the present study,
we have used PD-1xRAG1 −/− mice to examine the effects of PD-1 deficiency on ILC2. In addition, we also explored a potential mechanism for the control of PD-1 expression on ILC2 by the nuclear receptor PPAR-γ. 
| MATERIAL AND METHODS

| Mice
| Induction of ILC2 in vivo
RAG-1 −/− and PD-1xRAG1 mice −/− were injected with 300 ng of recombinant mouse IL-33 (rmIL-33) (Biolegend, San Diego, CA) intraperitoneal (IP) or intranasal (IN) every day for 3 days, and killed at day 4. Cells from the peritoneal cavity were collected by peritoneal wash after which, the collected cells were examined for surface markers and intracellular cytokines by flow cytometry as mentioned previously. To block PD-1, anti-PD-1 (clone RMP1-14, Bioxcell, NH) or control rat IgG were injected at 100 ng per mouse 1 day before IL-33 injection. The blocking of PD-1 was confirmed by flow cytometry using the same clone of PD-1. In experiments using papain, mice were injected IN with 10 μg per mouse consecutively for 3 days and mice were killed on day 4. For cells from the bronchoalveolar lavage (BAL), lungs were washed with two consecutive flushes of the lung with 1 mL phosphate-buffered saline (PBS). For lymphocyte isolation from the lungs, the lungs were finely chopped and digested with 0.13 U/mL Liberase (Roche, Switzerland) and 10 ug/mL DNase I (SigmaAldrich, UK) for 40 minutes at 37°C. Remaining tissue pieces were mashed through a 100 μM filter and the digestion reaction terminated by the addition of PBS containing 2% FCS (Sigma-Aldrich) on ice. The cells were run on a lymphoprep gradient for 12 minutes at 2200 RPM. The cells at the interface were collected and used in experiments.
| Generation of bone marrow-derived ILC2
ILC2 were generated from BM following a modified protocol used to generate ILC1. 22 In brief, BM cells were seeded at 1 × 10 6 cells/mL and cultured in RPMI 1640 medium (HyClone, South Logan, UT) supplemented with 10% fetal bovine serum (Biowhittaker, Verviers, Belgium), 250 IU/mL penicillin and streptomycin solution, 2 mM glutamine, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 1× nonessential amino acids and 1 mM sodium pyruvate (HyClone), and 50 µM β-mercaptoethanol (Gibco, Paisley, UK) and supplemented with 100 ng/mL recombinant mouse stem cell factor and 100 ng/mL recombinant mouse FLT3 ligand (ImmunoTools, Friesoythe, Germany). After 4 days, the cells were collected and the CD90 + cells were purified using anti-CD90 beads and magnetic sorting (Miltenyi Biotech). Cells were then stimulated with for further 4 days in fresh medium containing 10 ng/mL rmIL-7 and rmIL-33 (ImmunoTools). rmIL-2, rmIL-25, and rmTSLP were added also at 10 ng/mL. For 15dΔ12,14-PGJ 2 -(Sigma-Aldrich) and GW9662-(Sigma-Aldrich) treated ILC2 cultures, the drugs were added to the culture at the same time as IL-7 and IL-33 at 1 and 0.9 μM, respectively, and maintained for the duration of the culture. 
| Flow cytometry
) mice, we found no differences between the frequency of KLRG1 + cells ( Figure 1A ). In addition, Figure 3A) , however, this did not lead to a significant increase in the number of ILC2 collected from the mice ( Figure 3B ). Figure 3D ).
F I G U R E 3 Cytokine production by PD1
−/− ILC2 from the peritoneal exudate following IL-33 IP inoculation. A, Number of cells collected from the peritoneal exudate (*P < .05 Mann-Whitney test n = 7 mice from a total of three independent experiments) and (B) the number of ILC2 from the peritoneum of RAG1 Figure 4D ) expressing ILC2.
| PD1xRAG1
−/− ILC2 from peritoneal exudate does not express exhaustion markers
One possibility for the decrease in cytokine production by the ILC2 from PD1xRAG1 −/− mice is that chronic lack of PD-1 expression by these cells led to their exhaustion. Therefore, we examined the expression levels of CD39, CD244, LAG3, TIGIT, or TIM3, which have all been associated with PD-1 and T cell exhaustion. 24 However, Figure 5F ). Figure 5G ,H).
| Increased T-cell costimulator protein expression on PD-1 deficient ILC2 in vivo
The inducible T-cell costimulator protein (ICOS) has been identified as an important molecule in ILC2 homeostasis. The lack of ICOS ligand leads to both reduced KLRG1 expression on ILC2 and cytokine production by ILC2. 28 Since we had seen reduced cytokine production in the ILC2 from PD-1xRAG1
−/− mice, we investigated if this was due to reduced ICOS expression. However, ILC2 from PD-1xRAG1 −/− mice expressed higher levels of ICOS than ILC2 from RAG1 −/− mice (51 MFI ± 11 vs 36 MFI ± 13, respectively, P < .05 Figure 5I ,J). When we examined KLRG1 expression on the ILC2 from PD-1xRAG1 −/− mice, there was slightly higher expression but it was not significantly different from the expression on ILC2 from RAG1 −/− mice (271 MFI ± 156 vs 202 MFI ± 123, respectively, Figure 5K ,L). Thus, ICOS expression did not play a role in the reduced expression of Th2 cytokines in the ILC2 from the PD-1xRAG1 −/− mice.
| Generation of ILC2 from bone marrow
To examine ILC2 function in vitro, we developed a culture system to generate ILC2 from mouse bone marrow cells. Bone marrow cells were first incubated in Flt3 ligand and stem cell factor for 4 days after which they were selected for CD90 expression and recultured in rIL-7 and rIL-33 for a further 4 days. At the end of the 4 days, we found both CD90 Figure 6A,B) . Furthermore, these cells expressed GATA3, further demonstrating that these cells were ILC2 ( Figure 6C ). Similar to our observations in vivo, bone marrow-derived-ILC2 (bmILC2) generated from PD1xRAG1 −/− mice had a noticeable decrease in the frequency of IL-5 and IL-13 expressing cells when compared with wild type bmILC2 ( Figure 6D,E) . The reduced frequency of cytokine-producing ILC2 from PD1xRAG1 −/− mouse was not due to alterations in GATA3 expression, because the expression of GATA3 was equivalent in bmILC2 generated from both RAG1
−/− and PD1xRAG1 −/− ( Figure 6F ).
While IL-33 is important for the development of bmILC2, other cytokines such as IL-25 and TSLP have been shown to also be important for ILC2 in vivo. [29] [30] [31] Furthermore, IL-2 is important in stimulating IL-5 and IL-13 production by ILC2. 32 When bmILC2 were stimulated with IL-2, IL7, IL-25, IL-33, and TSLP, there was now no difference in the frequency of cytokineproducing bmILC2 from RAG1 −/− and PD1xRAG1 Figure 7A,B) . This suggested that these cytokines recover the production of IL-5 and IL-13 in the PD-1 deficient ILC2. Furthermore, by adding IL-2 to the cultures, the frequency of KLRG1 + bmILC2 increased in the cultures when compared with bmILC2 stimulated with IL7, IL-25, IL-33 and TSLP or IL-7 and IL-33 ( Figure 7C ). However, when comparing bmILC2 from RAG1 −/− and PD1xRAG1 −/− mice generated in the presence of IL-2, IL7, IL-25, IL-33, and TSLP, we did not observe major changes in the expression of GITR ( Figure 7D ) nor KLRG1 ( Figure 7E ). This suggested that in vivo GITR downregulation in PD1xRAG1 −/− mice maybe due to other factors, for example, interaction with its ligand.
| PPAR-γ promotes PD-1 expression on ILC2
PPAR-γ is a master regulator of adipocyte differentiation and a potent modulator of lipid metabolism, 33 a suppressor of proinflammatory cytokine secretion, 34 and has been being associated with Th2 cell immune responses. [35] [36] [37] In addition, PPAR-γ has also been identified as a hallmark for ILC2. 18 Similar to our previous findings, 35 when the PPAR-γ agonist 15dΔ12,14-PGJ 2 (PGJ2) was added to the bmILC2 cultures, there was almost a twofold increase in the expression levels of ST2 on the surface of ILC2 cultured with PGJ2 compared with bmILC2 cultured in the rIL-7 and rIL-33 alone (MFI ST2 115 ± 79 for control cultured vs 214 ± 158 for PGJ2 cultured ILC2, P < .05 paired t test; Figure 8A ). When the expression levels of PD-1 were examined, we found that expression of PD-1 was almost doubled on the bmILC2 that were stimulated with PGJ2 (MFI PD-1 245 ± 121 vs 449 ± 280, P < .005 paired t test, n = 7; Figures 8B and  S4A ). Similar observations were also made using another PPAR-γ agonist, pioglitazone ( Figure S4B ).
To further demonstrate that PPAR-γ might affect PD-1 expression, the PPAR-γ antagonist, GW9662, was added to the cultures. Expression of PD-1 was reduced by almost 45% on the ILC2 cultured with GW9662 compared with the control ILC2 (PD-1 MFI 148 ± 51 vs 83 ± 31, P < .005 paired t test, n = 5; Figures control-treated cells ( Figure S4D ). These data suggested that PPAR-γ could be a regulator of PD-1 expression on ILC2.
| DISCUSSION
In the present study, we found that chronic loss of PD-1 expression on ILC2 could affect the induction or maintenance of the production of IL-5 and IL-13 in vivo.
In addition, other costimulatory molecules GITR and ICOS also had altered expression in the chronic absence of PD-1. We could also demonstrate that PD-1 expression on ILC2 could be controlled by PPAR-γ. These data suggested that the expression of PD-1 on ILC2 might have physiological significance for not only ILC2 development but also for ILC2 function. Our results are slightly at odds with a previous publication that demonstrated that KLRG1
produce more Th2 cytokines following both IN delivery of IL-33 and during infection with the worm Nippostrongylus brasiliensis. 23 In our study, we found that there were no differences between ILC2 from RAG1 −/− and PD-1xRAG1 −/− mice in their expression of KLRG1.
Furthermore, we did not see increases in cytokine production in the ILC2 from PD-1xRAG1 −/− mice either in vitro or in vivo, but the levels were either reduced or similar when compared with RAG1 −/− mice. The reduction in the frequency of cytokine producing ILC2 from PD-1xRAG1 −/− mice was most pronounced when IL-33 was delivered into the peritoneum. One possible reason for these discrepancies between our study and that of Taylor et al 23 is that we used mice lacking RAG genes and these mice lack both T and B cells that might have feedback effects on ILC. In the study of Taylor et al, 23 IL-33 could still interact with T cells expressing ST2, 38 which might skew immune responses. 39 In addition, it has been found that IL-2 can increase IL-5 and IL-13 production by ILC2 32 and IL-2 would be an abundant cytokine in immunocompetent mice. In RAG1 −/− mice only ILC3s were found to be a major source of IL-2. In our studies, we concluded that chronic loss of PD-1 might have a greater effect on the ILC2 rather than an acute blocking of PD-1. However, we cannot rule out that microbiome differences between animal facilities could also explain differences between our study and Taylor et al. 40 For example, the mice in our study are maintained in IVC cages from birth and so these mice may have limited exposure to microbes which might alter immune responses. From our study, the reasons for why chronic PD-1 deficiency might reduce Th2 cytokine production could be explained by two hypotheses, which are not mutually exclusive. The first hypothesis centers on the recent finding that PD-1 is important for long-term responsiveness and function of memory CD8 T cells. In this study, Odorizzi et al 41 demonstrated that CD8 + T cells from mice lacking PD-1 produced less IFNγ and TNF 42-and 300-days postinfection with lymphocytic choriomeningitis virus than their WT counterparts. These authors hypothesized that PD-1 was important in preserving exhausted T cells from overstimulation, excessive proliferation, and terminal differentiation. Thus, in our study, it could be rationalized that PD-1 deficient ILC2 became too exhausted to make cytokines following prolonged exposure to IL-33. While possible, this would be a rapid realization of this effect of PD-1 on immune function, that is, within 3 days. Since anti-PD-1 antibody treatment did not significantly affect cytokine production by ILC2 in RAG1 −/− mice, this suggested that chronic lack of PD-1 might affect ILC2 development/activation rather than acute blocking with anti-PD-1. However chronic lack of PD-1 did not lead to any increase in the expression of markers associated with T cell exhaustion such as CD39, LAG3, TIM3, or TIGIT on the PD-1 deficient ILC2, which were observed on CD8 + T cells lacking PD-1. 41 An alternative hypothesis is that PD-1/PD-L2 interactions might be important in maintaining type 2 cytokine production by ILC2. PD-L2 expression on DCs is important in driving Th2 responses 15, 17 and more recently it was shown that ILC2 feedback on DC is important for driving Th2 memory responses. 42 Therefore, one can imagine that the lack of PD-1/PD-L2 interaction between DC and ILC2 could inhibit the feedback loops necessary to create a strong ILC2 response. Future studies using mice deficient in PD-L1 or PD-L2 could shed light on whether the ligands for PD-1 can affect ILC2 functions. Indeed, PD-L1 expression on ILC2 has recently been shown to be important in maintaining/inducing Th2 responses through PD-1 on Th2 cells. 43 In a house dust mite antigen model for allergy, mice lacking PD-1 were found to have exacerbated allergy responses compared with wild-type mice. 44 In this model, the authors found that the PD-1 deficient CD4 + T cells produced diminished levels of Th2 cytokines. This reduction in Th2 cytokines is therefore similar to our findings in the ILC2 cells. Since ILC2 are the early source of Th2 cytokines and could potentially affect CD4 T cells 43 just as NK cells have been found to affect adaptive immune responses, 45 it is tempting to speculate that reduced Th2 cytokine production by PD-1 deficient ILC2 might skew the CD4 T cell responses in PD-1 deficient mice. Cells in adipose tissue express high levels of PD-1 and PPAR-γ, 46, 47 suggesting that the interplay, whether direct or indirect, between these two molecules might play important role in fat metabolism. PD-1 can play a role in controlling T cell metabolism, 48 thus it is tempting to hypothesize that the PPAR-γ-PD-1 axis might also help to control cellular metabolism. The fact that we observed that PPAR-γ could modulate PD-1 and ST2 expression on ILC2 might imply two scenarios. In the first scenario, PPAR-γ has direct effects on both PD-1 and ST2 independently of each other, while the second scenario would imply that PPAR-γ by affecting the expression of either ST2 or PD-1 then affects the expression of the other. In support of the first scenario, we have found in the present study that lack of PD-1 does not affect ST2 expression on ILC2 and furthermore increased expression of ST2 induced by the short-chain fatty acid butyrate or histone deacetylase inhibitors does not correspondingly lead to increased PD-1 expression on the ILC2 ( Figure S5 ). Thus if PPAR-γ can directly affect PD-1 expression, antagonists of PPAR-γ might be useful in directing antitumor immune responses where PD-1 interactions with its ligands play a role in dampening immune responses to tumors. 14 Therefore, the interplay between PPAR-γ and PD-1 in inflammation relating to cancer and metabolic syndromes is an area that should be further explored.
In the present study, we have demonstrated that chronic loss of PD-1 expression on ILC2 might have a role in maintaining cytokine production in these cells and expression of receptors associated with ILC2 function. Since ILC2 can express PD-1 23, 25 and with current anti-PD-1 or anti-PD-L1 therapies for the treatment of cancers, 14 it would be interesting to examine whether some of the functions associated with ILC2 are also affected in these patients. For example, skewing of Th2 cytokines might have both beneficial as well as detrimental effects on tumor therapies. 49 
